{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:16:06Z","timestamp":1765628166736,"version":"3.48.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,13]]},"DOI":"10.7759\/cureus.99107","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:11:16Z","timestamp":1765627876000},"source":"Crossref","is-referenced-by-count":0,"title":["Atypical Oral Presentation of Giant Cell Arteritis With Subsequent Middle Cerebral Artery Involvement"],"prefix":"10.7759","author":[{"given":"Alamin","family":"Alkundi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0608-7","article-title":"A new era for giant cell arteritis","volume":"34","author":"Lyons HS","year":"2020","unstructured":"Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. A new era for giant cell arteritis. Eye (Lond). 2020, 34:1013-1026. 10.1038\/s41433-019-0608-7","journal-title":"Eye (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder GG","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, et al.. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990, 33:1122-1128. 10.1002\/art.1780330810","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002866","article-title":"Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study","volume":"9","author":"Hemmig AK","year":"2023","unstructured":"Hemmig AK, Aschwanden M, Seiler S, et al.. Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study. RMD Open. 2023, 9:10.1136\/rmdopen-2022-002866","journal-title":"RMD Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02433-y","article-title":"Giant cell arteritis: reviewing the advancing diagnostics and management","volume":"37","author":"Bilton EJ","year":"2023","unstructured":"Bilton EJ, Mollan SP. Giant cell arteritis: reviewing the advancing diagnostics and management. Eye (Lond). 2023, 37:2365-2373. 10.1038\/s41433-023-02433-y","journal-title":"Eye (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06739-w","article-title":"Diagnostic delay in patients with giant cell arteritis: results of a fast-track clinic","volume":"43","author":"van Nieuwland M","year":"2024","unstructured":"van Nieuwland M, Colin EM, Boumans D, Vermeer M, Brouwer E, Alves C. Diagnostic delay in patients with giant cell arteritis: results of a fast-track clinic. Clin Rheumatol. 2024, 43:349-355. 10.1007\/s10067-023-06739-w","journal-title":"Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit F","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016, 315:2442-2458. 10.1001\/jama.2016.5444","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330803","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods","volume":"33","author":"Bloch DA","year":"1990","unstructured":"Bloch DA, Michel BA, Hunder GG, et al.. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthritis Rheum. 1990, 33:1068-1073. 10.1002\/art.1780330803","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-019-1225-9","article-title":"Giant cell arteritis: is the clinical spectrum of the disease changing?","volume":"19","author":"Gonz\u00e1lez-Gay M\u00c1","year":"2019","unstructured":"Gonz\u00e1lez-Gay M\u00c1, Ortego-Jurado M, Ercole L, Ortego-Centeno N. Giant cell arteritis: is the clinical spectrum of the disease changing?. BMC Geriatr. 2019, 19:200. 10.1186\/s12877-019-1225-9","journal-title":"BMC Geriatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111005","article-title":"Increase in age at onset of giant cell arteritis: a population-based study","volume":"69","author":"Kermani TA","year":"2010","unstructured":"Kermani TA, Sch\u00e4fer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, Warrington KJ. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010, 69:780-781. 10.1136\/ard.2009.111005","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(99)80193-7","article-title":"Occult giant cell arteritis: ocular manifestations","volume":"125","author":"Hayreh SS","year":"1998","unstructured":"Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998, 125:521-526. 10.1016\/s0002-9394(99)80193-7","journal-title":"Am J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq039a","article-title":"BSR and BHPR guidelines for the management of giant cell arteritis","volume":"49","author":"Dasgupta B","year":"2010","unstructured":"Dasgupta B, Borg FA, Hassan N, et al.. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010, 49:1594-1597. 10.1093\/rheumatology\/keq039a","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002147","article-title":"Tongue necrosis in giant cell arteritis","volume":"45","author":"Zhong L","year":"2025","unstructured":"Zhong L, Roberts KF, Chen H, Van Stavern GP, Stunkel L. Tongue necrosis in giant cell arteritis. J Neuroophthalmol. 2025, 45:e79-e80. 10.1097\/WNO.0000000000002147","journal-title":"J Neuroophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/BF03043512","article-title":"Oral manifestations of giant cell arteritis","volume":"1","author":"van der Wal JE","year":"1997","unstructured":"van der Wal JE, van der Waal I. Oral manifestations of giant cell arteritis. Mund Kiefer Gesichtschir. 1997, 1:65-67. 10.1007\/BF03043512","journal-title":"Mund Kiefer Gesichtschir"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307614","article-title":"Stroke associated with giant cell arteritis: a population-based study","volume":"86","author":"Samson M","year":"2015","unstructured":"Samson M, Jacquin A, Audia S, et al.. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 2015, 86:216-221. 10.1136\/jnnp-2014-307614","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03468-6","article-title":"Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry","volume":"27","author":"Molina-Collada J","year":"2025","unstructured":"Molina-Collada J, Dom\u00ednguez-\u00c1lvaro M, Melero-Gonz\u00e1lez RB, et al.. Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry. Arthritis Res Ther. 2025, 27:4. 10.1186\/s13075-024-03468-6","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven A","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003, 49:703-708. 10.1002\/art.11388","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1711031","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Akiyama M","year":"2017","unstructured":"Akiyama M. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017, 377:1493-1495. 10.1056\/NEJMc1711031","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426626-atypical-oral-presentation-of-giant-cell-arteritis-with-subsequent-middle-cerebral-artery-involvement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:11:16Z","timestamp":1765627876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426626-atypical-oral-presentation-of-giant-cell-arteritis-with-subsequent-middle-cerebral-artery-involvement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.99107","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,13]]}}}